Skip to main content
Equibles
MIRM logo

MIRM · Mirum Pharmaceuticals, Inc. · Investor Relations

Track MIRM — free

Use MIRM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MIRM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$93.99 +0.66 (+0.71%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$6.14B
Shares
65.28M
Volume · Nov 13 331.08K Avg daily vol (3M) 680.13K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-11-17 12:30 UTC 2026 Jefferies Global Healthcare Conference Conference

Recent news

Date Headline
2026-11-12 Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-10 Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD
2026-11-03 Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-02 Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD’s The Liver Meeting® 2026
2026-10-27 Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
2026-10-26 Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva
2026-10-21 Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-10-15 Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-12 Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
2026-10-11 Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
2026-09-28 Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
2026-09-27 Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
2026-09-25 Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
2026-09-14 Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-08 Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
2026-09-02 Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-08-11 Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-05 Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-29 Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
2026-07-13 Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-14 Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
2026-06-11 Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-04 Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
2026-05-30 Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
2026-05-21 Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

Past events

Date Event Type
2026-11-11 Stifel 2026 Healthcare Conference Conference
2026-11-10 Wolfe Research Healthcare Conference 2026 Conference
2026-11-03 Mirum Pharmaceuticals, Inc. Q3 FY2026 Earnings Call Earnings call
2026-10-12 Mirum Pharmaceuticals Business Update Call Event
2026-09-28 Mirum Pharmaceuticals Business Update Call Event
2026-09-16 Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-09-15 H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-09-10 Citi’s 2026 Biopharma Back-to-School Conference Conference
2026-09-09 Cantor 2026 Global Healthcare Conference Conference
2026-08-05 Mirum Pharmaceuticals, Inc. Q2 FY2026 Earnings Call Earnings call
2026-05-20 2026 RBC Capital Markets Global Healthcare Conference Conference
2026-05-19 H.C. Wainwright 4th Annual BioConnect Investor Conference Conference
2026-05-06 Mirum Pharmaceuticals, Inc. Q1 FY2026 Earnings Call Earnings call
2026-05-04 Mirum Pharmaceuticals Business Update Call Event
2026-03-11 2026 Leerink Partners Global Healthcare Conference Conference
2026-03-10 The Citizens Life Sciences Conference Conference
2026-03-10 Barclays 28th Annual Global Healthcare Conference Conference
2026-03-02 TD Cowen’s 46th Annual Health Care Conference Conference
2026-03-02 TD Cowen's 46th Annual Health Care Conference Conference
2026-02-25 Mirum Pharmaceuticals, Inc. Q4 FY2025 Earnings Call Earnings call
2026-01-14 44th Annual J.P. Morgan Healthcare Conference Conference
2025-12-08 Mirum Pharmaceuticals Business Update Call Event
2025-12-03 Citi’s 2025 Global Healthcare Conference Conference
2025-12-02 8th Annual Evercore Healthcare Conference Conference
2025-11-12 J.P. Morgan U.S. Opportunities Forum 2025 Event

Source: https://ir.mirumpharma.com/overview/default.aspx

Key facts CIK 1759425 CUSIP 604749101 13F (30d) 243 filings 219 filers Visit website Investor relations